Presentation (CTI)

OBJECTIVES: This study analyzes the outcomes of the International Reference Pricing (IRP) system for original medicines in Türkiye during 2024. The IRP system in Türkiye determines the list price of medicines by referencing the lowest manufacturer’s sale price among designated reference countries and considers equivalent medicines available in the domestic market and newly introduced products.
METHODS: The analysis was conducted using the Detailed Medicine Price List published by the Turkish Medicines and Medical Devices Agency on December 30, 2024. The study focused exclusively on original medicines. Medicines were excluded if they were generic, non-reimbursed, over-the-counter, single-source generics without equivalents, traditional herbal medicinal products, or if Türkiye or multiple countries were listed as reference countries. Data were evaluated using Microsoft Excel, focusing on manufacturer sale prices, reference prices, country-based distribution, and medicine classification.
RESULTS: A total of 2,389 original medicines were included in the analysis. The average manufacturer’s sale price in Türkiye was ₺11,780.84, while the average reference price from the source countries was €718.77. The leading reference countries were Greece (20.02%), France (15.79%), Italy (13.69%), Spain (12.19%), Germany (9.13%), Portugal (4.27%), and Switzerland (4.31%). The number of medicines referenced from each country was as follows: Greece (478), France (377), Italy (327), Spain (291), Germany (218), Portugal (102), and Switzerland (103). Germany exhibited a higher average manufacturer sale price than the other reference countries, which is ₺32,509.
CONCLUSIONS: Greece remained the most frequently used reference country for pricing original medicines in 2024. Compared to 2023, the total number of original medicines increased. While the distribution of reference countries remained relatively stable, the average price of original medicines in Türkiye showed a notable increase.